We detected some significant differences between the discovery and validation groups for sex, diagnosis, rheumatoid factor (RF) and antibodies to anti-citrullinated proteins (ACPA), likely due to the relatively low number of patients with definite RA in the validation group (Supplementary Table 2). The gene discussed is PRTN3; the disease is rheumatoid arthritis.